Ethereum options open interest increased nearly 10% to $5.85 billion, with daily trading volume at $2.7 billion. Call options hold the majority share of open interest and daily volume, indicating bullish positioning, but the most traded contract was a $2,000 put, showing some traders are hedging against price drops. Leading contracts by open interest are December 2026 calls, while the top daily volume contract is a November 2026 put. This mix suggests active hedging and diverse strategies among investors in the Ethereum options market.
Ethereum options open interest reached $5.85 billion with a daily volume of $2.7 billion, highlighting active trading strategies. For readers following the broader crypto market, here is Pluang's snapshot as of Oct 31, 2026 18:21 WIB: out of 50 major cryptocurrencies, 28 rose and 19 fell. Among notable movers, EGLD gained 2.84% with 61% buy orders, contrasting with ENJ which rose 2.82% but had 65% sell orders, while GRT increased 2.53% with 70% buy orders.
From October 27 to 31, Bitcoin traded at a discount on Coinbase compared to Binance, signaling subdued U.S. buying pressure despite a 38% rise in institutional trading volume on Coinbase Prime. CME data shows more short Bitcoin futures than longs, in...
A credential-theft campaign named TrapDoor has been discovered, involving over 34 malicious packages and 384 versions targeting developers in the crypto and decentralized finance (DeFi) space, including those working within the Solana blockchain ecos...
Following Binance's $6.3 billion security breach, Ripple successfully froze $40.5 million in stolen RLUSD tokens linked to the attackers, preventing further unauthorized withdrawals. However, Ripple could not freeze $296 million worth of native XRP s...
On March 1, 2026, an exploit in Curve Finance's sDOLA/crvUSD LlamaLend market led to estimated losses of 822,475 crvUSD for 27 borrowers. The attack used a two-part flash loan to hard-liquidate positions, involving over 11.7 million crvUSD in collate...
Aura Biosciences is positioned as a low-risk, fully funded company focusing on bel-sar treatment for early choroidal melanoma, with pivotal Phase 3 trial data expected in 2027. The company holds $323.8 million in cash as of June 2026, supporting oper...
